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Background: Impaired kidney function is an established predictor of mortality after acute nonvariceal upper
gastrointestinal bleeding (ANVUGIB); however, which factors are associated with mortality after ANVUGIB among
patients undergoing dialysis is unknown. We examined the associations among demographic characteristics,
dialysis-specific features, and comorbid conditions with short-term mortality after ANVUGIB among patients on
dialysis.
Methods: Design: Retrospective cohort study. Setting: United States Renal Data System (USRDS), a nation-wide
registry of patients with end-stage renal disease. Participants: All ANVUGIB episodes identified by validated
algorithms in Medicare-covered patients between 2003 and 2007. Measurements: Demographic characteristics and
comorbid conditions from 1 year of billing claims prior to each bleeding event. We used logistic regression
extended with generalized estimating equations methods to model the associations among risk factors and 30-day
mortality following ANVUGIB events.
Results: From 2003 to 2007, we identified 40,016 eligible patients with 50,497 episodes of ANVUGIB. Overall 30-day
mortality was 10.7% (95% CI: 10.4-11.0). Older age, white race, longer dialysis vintage, peritoneal dialysis (vs. hemodialysis),
and hospitalized (vs. outpatient) episodes were independently associated with a higher risk of 30-day mortality.
Most but not all comorbid conditions were associated with death after ANVUGIB. The joint ability of all factors
captured to discriminate mortality was modest (c=0.68).
Conclusions: We identified a profile of risk factors for 30-day mortality after ANVUGIB among patients on dialysis
that was distinct from what had been reported in non-dialysis populations. Specifically, peritoneal dialysis and
more years since initiation of dialysis were independently associated with short-term death after ANVUGIB.
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Acute nonvariceal upper gastrointestinal bleeding
(ANVUGIB) is common among patients on dialysis
and associated with poor outcomes. Using a stringent
criterion to ascertain ANVUGIB events from Medicare
claims, the occurrence rate of ANVUGIB among patients
on dialysis was estimated at 57 episodes per 1000
person-years [1], almost two orders of magnitude higher
than in the general population. Approximately 12% of* Correspondence: wcw1@stanford.edu
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reproduction in any medium, provided the orpatients died within 30 days after the event [1]. Wasse
et al. have previously analyzed the United States Renal
Data System (USRDS) to identify risk factors for incident
upper gastrointestinal bleeding (UGIB) among patients
with end-stage renal disease (ESRD) [2]. However, there
are no reports on the risk factors for outcomes after UGIB
in this population.
Although ANVUGIB is a potentially life-threatening
condition, most patients in the general population are
at low risk for mortality and often die from other
complications, rather than from bleeding itself [3].
Determinants of mortality following ANVUGIB in the
general population included age, certain comorbiditiesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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function, and malignancy), specific endoscopic findings,
and biometric and laboratory data at presentation (such as
blood pressure and hemoglobin concentrations) [4-7]. We
conducted the present study to establish predictors of
30-day mortality after ANVUGIB in a national cohort of
U.S. patients undergoing dialysis. While we expected
several established risk factors for mortality on dialysis
to also be associated with short-term mortality after
ANVUGIB, we focused on identifying risk factors that
are of particular pertinence to the bleeding event, such
as history of earlier ANVUGIB episodes, whether the
bleeding was peptic ulcer-related, as well as the care setting
of its diagnosis and the most recent dialysis modality
before the event. We also hypothesized that risk factors
might be modified by age, sex, race, and dialysis modality.
Methods
Data source
We used the USRDS database for this study. The USRDS
contains health care claims submitted by providers
to Medicare on most patients with ESRD receiving
maintenance dialysis care or kidney transplantation in
the U.S. Most patients with ESRD qualify for Medicare
coverage independent of their age, which enables research
on a large number of subjects younger than 65 years, a
population for whom Medicare claims are usually not
available.
Study population
We analyzed all patients who underwent maintenance
dialysis in the US between January 1, 2003 and December
31, 2007. Only those patients continuously covered by
traditional fee-for-service Medicare at least for one year
before the ANVUGIB episode were included to ensure
adequate and uniform ascertainment of comorbidities.
Patients under the age of 18 years or whose kidney function
recovered were excluded.
Identification of ANVUGIB episodes
From claims collected during periods of Medicare eligibility
only, we identified ANVUGIB events using a modified
stringent criterion proposed by Targownik et al. [8]. As
described in recent work [1], ANVUGIB events were
defined from a group of ICD-9 diagnostic codes,
which specify the identified cause of the bleeding,
such as gastroesophageal laceration-hemorrhage (530.7)
or gastric ulcer with hemorrhage (531.0). Additionally
we included several important lesion-specific events
not considered by Targownik et al. [8] (e.g., 537.83
for angiodysplasia of stomach and duodenum with
hemorrhage; 537.84 for Dieulafoy lesion (hemorrhagic)
of stomach and duodenum). Detailed codes are listed
in Additional file 1.To avoid lack of specificity while ascertaining ANVUGIB
events from outpatient claims, we defined a single
ANVUGIB event based on the presence of two outpatient
claims within a 7-day time period. Alternatively, one
outpatient claim was considered sufficient if it was
accompanied by a claim for esophagogastroduodenoscopy
performed on the same date [9]. Further, if the onset dates
of two events were within a 30-day period, these two
events were counted as a single episode and the earlier
event was used as the index date marking the beginning
of follow-up [9].
Study outcomes
The primary outcome of interest was short-term (30-day)
mortality following an episode of ANVUGIB, defined as
having died within 30 days of the ANVUGIB diagnosis
date regardless of discharge status [9,10].
Candidate predictors
We obtained patient-level characteristics such as age,
sex, race, vintage (time since first ESRD date), and the
presumed primary kidney disease causing ESRD from the
Medical Evidence Report CMS-2728. We ascertained the
most recent dialysis modality (hemodialysis vs. peritoneal
dialysis) and any history of kidney transplantation
from treatment history files. We used the 60-day file
constructed from the detailed file to avoid the concern
that patients had been switched the modality just for the
event. We ascertained a large number of comorbidities
from one year of inpatient and outpatient claims preceding
the ANVUGIB event using validated algorithms,
where available: diabetes, heart failure, coronary artery
disease, chronic obstructive pulmonary disease, cerebral
vascular disease, hypertension, arrhythmia, valvular heart
disease, peripheral vascular disease, chronic liver disease,
and malignancy [1]. To define prior ANVUGIB history,
we traced back to all available claims in our database
(since 1996).
Statistical analysis
We used logistic regression models to evaluate the
associations among potential risk factors and 30-day
mortality. As each subject was eligible to contribute more
than one episode, correlations among observations within
subject are expected. We applied generalized estimating
equations (GEE) with an exchangeable working correlation
structure to adjust for the expected dependence of
observations within each patient [11]. Since only 0.04% and
0.35% patients had their race and dialysis modality missing,
respectively, we conducted complete case analyses.
We were a priori interested in the interactions of age,
sex, race, and dialysis modality with other risk factors. To
avoid over fitting the data while exploring for interactions
among covariates, we randomly split our data into a
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this exploratory phase, we fit logistic regression models
assuming independence of observations where each
interaction was added as a covariate to the main effects
model. We applied the minimum Akaike information
criterion (AIC) procedure [12], which selects the model
with the smallest AIC among the set of models tested.
Each model’s AIC is computed in the validation sample
using parameter estimates from the derivation sample. If a
significant interaction were to be found in the derivation
sample, its significance would be validated by a decline in
AIC value in the validation sample.
Once the final model was found, which included all
covariates and validated interactions, it was fit in the
full sample using GEE. We reported unadjusted and
multivariable-adjusted odds ratios (OR) and 99% confi-
dence intervals (CI) for each factor. All analyses were
performed using SAS 9.2 software (The SAS Institute Inc,
Cary, NC).
This work was approved by the Institutional Review
Board of Stanford University School of Medicine and
conducted under a data use agreement to Dr. Winkelmayer
from the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK). This manuscript was reviewed
by NIDDK and approved for submission.
Results
From 2003 to 2007, we identified 50,497 eligible episodes
of ANVUGIB, which were experienced by 40,016 unique
patients. The number of episodes per patient ranged from
1 to 14 [10th percentile: 1; 90th percentile: 2]. Characteristics
of the study population are shown in Table 1: the average
age was 63 years and slightly more than half of the episodes
were in men and in whites. The vast majority of episodes
occurred in patients undergoing HD (93.6%), and the
median time since first ESRD treatment was 3.8 years. All
comorbidities were highly common; almost two-thirds
had diabetes and almost three-quarters had been diagnosed
with hypertension in the previous year. One-third of
episodes (17,645) occurred in patients in whom a previous
episode was recorded and 40.6% (7,164) of those previous
episodes occurred before 2003. The diagnosis most
commonly identifying ANVUGIB episodes was gastritis or
duodenitis with hemorrhage (29.1%, Table 2).
Five thousand, four hundred and thirteen patients
died within 30 days of ANVUGIB, representing 13.5%
of patients and 10.7% of episodes. Table 3 lists the
unadjusted and multivariable-adjusted OR and 99% CI
of all independent variables considered in this study. The
full model exhibited only modest discrimination with a c
statistic of 0.68 and an R2 of 0.04. The 30-day death rate
in the lowest decile of predicted probabilities of death was
2.3%, as compared to 21.9% in the highest decile. Older
age, white race, longer dialysis vintage, peritoneal dialysis(vs. hemodialysis), and hospitalized (vs. outpatient) epi-
sodes were associated with higher risk of 30-day mortality
after ANVUGIB. Patients with no recorded history of
ANVUGIB were more likely to die within 30 days after an
episode. Most comorbidities were associated with 30-day
mortality after ANVUGIB except for diabetes mellitus,
coronary artery disease (main effect OR: 1.04; 99% CI
0.92-1.18), and hypertension.
Only one interaction satisfied the validation criteria
outlined in the Methods section (see Additional file 2):
sex modified the association between coronary artery
disease and 30-day mortality after ANVUGIB, where the
odds of death were 13% lower in men with coronary
artery disease than those without, whereas there was no
association between coronary artery disease and death in
women (Table 3).
Discussion
We built a contemporary cohort using validated stringent
algorithms and captured initial and repeat ANVUGIB
episodes. Our sample size was uniquely and sufficiently
large to empower us to investigate thoroughly numerous
factors and interactions even under a very stringent type I
error (0.01) and to split our data to avoid reporting
false positive interactions. Furthermore, we tested the
associations between dialysis specific parameters (such as
dialysis modality and dialysis vintage) and ANVUGIB
mortality for the first time. To our knowledge, this is the
first population-based claims data analysis dedicated to
studying risk factors for short-term mortality after
ANVUGIB in patients on dialysis.
Cardiovascular disease, current smoking, and risk
factors suggesting more disability had been reported to
associate with a higher risk of UGIB among patients with
ESRD [2]. In addition, we found several dialysis-specific
parameters, such as using peritoneal dialysis rather than
hemodialysis and longer dialysis vintage, to be associated
with short-term mortality. Other predictors including
older age and presence of most comorbid conditions were
also associated with 30-day mortality, results not dissimilar
from studies from non-ESRD populations. Furthermore,
these factors are also risk factors for mortality in ESRD
patients in general, even in the absence of ANVUGIB.
It was previously reported that most patients (79.7%)
who experienced an ANVUGIB episode died of causes
that were not directly bleeding-related. In a study of
more than 10,000 patients in Hong Kong with peptic
ulcer disease-related bleeding, Sung et al. showed that
multi-organ system failure (23.9%), pulmonary conditions
(23.5%) and terminal malignancy (33.78%) were the
most common causes of death [3]. As a result, age,
comorbidities and general health conditions were
consistently found to be strong predictors of ANVUGIB
mortality, whereas bleeding-specific parameters such as
Table 1 Patient characteristics at each episode, by 30-day survival status
All episodes Survived Deaths
Number (row %) 50497 45084 (89.3) 5413 (10.7)
Age (years; ± standard deviation) 62.9 (±14.7) 62.3 (±14.8) 68.0 (±13.2)
18 to <50 years (%) 10232 (20.3) 9670 (21.4) 562 (10.4)
50 to <65 years (%) 15148 (30.0) 13775 (30.6) 1373 (25.4)
65 to <75 years (%) 13492 (26.7) 11864 (26.3) 1628 (30.1)
≥75 years (%) 11625 (23.0) 9775 (21.7) 1850 (34.2)
Male 27025 (53.5) 24092 (53.4) 2933 (54.2)
Race
White (%) 25962 (51.4) 22770 (50.5) 3192 (59.0)
Black (%) 21771 (43.1) 19849 (44.0) 1922 (35.5)
Other (%) 2764 (5.5) 2465 (5.5) 299 (5.5)
Dialysis modality
Hemodialysis (%) 47274 (93.6) 42277 (93.8) 4997 (92.3)
Peritoneal dialysis (%) 3223 (6.4) 2807 (6.2) 416 (7.7)
Dialysis vintage [years; median (IQR)] 3.8 (2.2; 6.2) 3.8 (2.2; 6.2) 4.0 (2.3; 6.4)
≥6 years (%) 13463 (26.7) 11959 (26.5) 1504 (27.8)
3 to <6 years (%) 17696 (35.0) 15821 (35.1) 1875 (34.6)
1 to < 3 years (%) 19338 (38.3) 17304 (38.4) 2034 (37.6)
History of comorbid conditions
Diabetes (%) 32181 (63.7) 28625 (63.5) 3556 (65.7)
Hypertension (%) 36939 (73.2) 32925 (73.0) 4014 (74.2)
Coronary artery disease (%) 15147 (30.0) 13299 (29.5) 1848 (34.1)
Cerebral vascular disease (%) 8750 (17.3) 7538 (16.7) 1212 (22.4)
Heart failure (%) 26833 (53.1) 23437 (52.0) 3396 (62.7)
Arrhythmia (%) 20392 (40.4) 17596 (39.0) 2796 (51.7)
Valvular heart disease (%) 15379 (30.5) 13310 (29.5) 2069 (38.2)
Peripheral vascular disease (%) 18792 (37.2) 16231 (36.0) 2561 (47.3)
Chronic obstructive lung disease (%) 13927 (27.6) 11998 (26.6) 1929 (35.6)
Any cancer (%) 4335 (8.6) 3588 (8.0) 747 (13.8)
Upper gastrointestinal cancer* (%) 250 (0.5) 198 (0.4) 52 (1.0)
Chronic liver disease (%) 6423 (12.7) 5530 (12.3) 893 (16.5)
History of kidney transplant (%) 3119 (6.2) 2849 (6.3) 270 (5.0)
History of ANVUGIB (%) 17645 (34.9) 16021 (35.5) 1624(18.9)
Abbreviation: IQR – interquartile range.
* Upper gastrointestinal cancer (ICD-9 diagnosis codes 150–152).
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not consistently associated with short-term outcome of
ANVUGIB [6,13]. As expected, we showed that advanced
age, hospitalized episodes, and most co-morbidities were
independently associated with 30-day mortality after
ANVUGIB among patients on dialysis, similar to findings
from the general population, while bleeding from peptic
ulcer disease rather than from any other cause did not
significantly associate with short-term mortality after
ANVUGIB. Although only 12.7% patients on dialysis had
chronic liver disease, it was the most prominent predictor
among all comorbidities in the full model (OR: 1.59; 99%CI: 1.43 to 1.76). In other studies of patients in the general
population who experienced an upper gastrointestinal
bleed, mortality following variceal hemorrhage was found
to be higher than after ANVUGIB [6,10]. However, even
for ANVUGIB, cirrhosis and liver failure were important
comorbidities to predict mortality [5,6], which our study
now confirms in a dialysis population. Similarly, patients
with malignancy were more likely to die after UGIB both
in the dialysis and the general population [4,5,14].
We found the association between CAD and mortality
to be overall null, but modified by sex in that men, but not
women, had a lower risk of mortality after a ANVUGIB




Esophageal ulcer/hemorrhage 6,370 12.6%
Gastric ulcer with hemorrhage 9,788 19.4%
Duodenal ulcer with hemorrhage 5,152 10.2%
Peptic ulcer with hemorrhage 1,166 2.3%
Gastrojejunal ulcer with hemorrhage 397 0.8%
Gastritis/duodenitis with hemorrhage 14,702 29.1%
Angiodysplasia/Dieulafoy lesion with hemorrhage 4,479 8.9%
Hematemesis 17,643 34.9%
Note: A single episode might have had more than one diagnosis associated
with it.
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without CAD). Rockall et al. reported an unadjusted odds
ratio for mortality of 4.3 (95% CI: 3.2-5.8) of ischemic heart
disease in a prospective multicenter study of 4,185 cases of
acute upper gastrointestinal bleeding [4]. By contrast, Klebl
et al. found more cardiovascular disease (53.8% vs. 39.6%)
among those who survived upper gastrointestinal bleeding
than among those who died [15]. Several other studies
reported only unspecified cardiovascular comorbidity as a
risk factor for ANVUGIB related mortality [5,7,14,16].
Regarding aspirin use, two studies reported associations
between use of aspirin and lower 30-day mortality [13,15],
whereas others found no such association [5,7]. In
reviewing the evidence, it appears that patients with
ischemic heart disease represent a unique subgroup of
ANVUGIB patients, perhaps with a different patho-
physiology of bleeding, and further evaluation of ischemic
heart disease as a risk factor for mortality after ANVUGIB
is needed.
Our finding that patients undergoing peritoneal dialysis
had higher short-term mortality after an ANVUGIB event
compared with otherwise similar patients on hemodialysis
is interesting. The association between dialysis modality
and mortality has been widely studied, and it appears that
older patients, especially women and those with diabetes,
and those with longer vintage experienced better survival
on hemodialysis [17-20]. We did not find any interactions
among dialysis modality and these factors. While it is
possible that peritoneal dialysis patients are more vulner-
able when they experience an ANVUGIB, e.g. due to their
altered gastrointestinal hemodynamics and physiology, it
is also possible that patients undergoing hemodialysis
receive more frequent medical surveillance, including
monitoring of anemia, and ANVUGIB may thus be more
likely to be detected earlier and treated more aggressively.
Whether dialysis adequacy correlated with short-term
outcome after ANVUGIB or not could not be answered
in current study. It is possible that some patientsundergoing peritoneal dialysis may achieve lower clearance
and be more uremic, which may then contribute to worse
bleeding, reduced hemostasis, and increased mortality risk.
There was a graded increase of risk among patients with
longer vintage. The association with vintage became
significant mainly after adding age and prior ANVUGIB
history into the model. The percentage of prior ANVUGIB
increased with longer vintage (29.4%, 36.2% and 41.3% for
vintage 1–3 years, 3–6 years and >6 years respectively),
while age was negatively correlated with vintage (r=−0.19,
p<0.001). Because prior ANVUGIB and younger age were
associated with better outcomes, they confounded the
association of vintage in the unadjusted model. Compared
to those with dialysis vintage between 1 and 3 years, the
odds ratios for 30-day mortality after ANVUGIB were 1.11
(99% CI: 1.01-1.21) and 1.37 (99% CI: 1.24-1.52) for those
with dialysis vintage of 3–6 years and more than 6 years
respectively. Longer duration of dialysis is associated with
more severe dialysis or uremia related complications,
such as cardiovascular calcification [21] or systemic
amyloidosis [22-24]. These complications might weaken
the capacity of patients on dialysis to pass through the
stress of ANVUGIB. In addition, these complications may
reduce the patient’s capability to achieve hemostasis once
a bleeding occurs.
Prior history of ANVUGIB is another rarely mentioned
factor for mortality after ANVUGIB, which is important
especially for dialysis patients who are at particular risk of
recurrence [1,25,26]. The longitudinal nature of the
USRDS provided useful information on previous events,
which could not be observed in other (prospective)
cohorts with short inclusion and observation periods
[4,5,7,15]. In a study of patients without ESRD, a
history of bleeding ulcers was associated with bleeding
continuation/re-bleeding within 30 days of the initial
ANVUGIB episode, but not with 30-day mortality [13]. In
our study, we considered re-bleeding within 30 days as
being part of the same episode. We observed a 24% lower
mortality for patients with a historical claims indicating
prior ANVUGIB. However, this finding may reflect
survivor bias, a special case of selection bias, or may
be confounded by the duration of Medicare coverage
prior to the index event. Patients who survived a previous
episode of ANVUGIB may be more robust in ways that is
beyond what can be observed in a claims dataset. In
addition, such episodes may have been milder bleeds, and
be followed by other milder bleeding episodes. Further,
patients who survived previous bleeds may have received
adequate intervention, medical treatment, or heightened
surveillance, leading to milder subsequent bleeding
episodes. Unfortunately, the USRDS does not contain
information on medications including eradication of
H. pylori or long-term proton pump inhibitor therapy.
Our findings also suggest that clinicians need to be
Table 3 Odds ratios for 30-day mortality after acute nonvariceal upper gastrointestinal bleeding
Odds ratio (99% Confidence Interval)
Variable Category Unadjusted Adjusted
Age 18 to <50 years 1.0 (reference) 1.0 (reference)
50 to <65 years 1.71 (1.49 to 1.95) 1.54 (1.34 to 1.77)
65 to <75 years 2.35 (2.06 to 2.68) 2.04 (1.77 to 2.35)
≥75 years 3.24 (2.84 to 3.69) 2.79 (2.42 to 3.21)
Sex (Males vs. females)* 1.03 (0.96 to 1.11)
Among patients with CAD 0.94 (0.82 to 1.07)
Among patients without CAD 1.12 (1.02 to 1.23)
Race White 1.0 (reference) 1.0 (reference)
Black 0.69 (0.64 to 0.75) 0.80 (0.73 to 0.87)
Others 0.86 (0.73 to 1.02) 0.96 (0.81 to 1.13)
Vintage 1 to <3 years 1.0 (reference) 1.0 (reference)
3 to <6 years 1.02 (0.93 to 1.11) 1.11 (1.01 to 1.21)
≥6 years 1.08 (0.98 to 1.18) 1.37 (1.24 to 1.52)
Dialysis modality peritoneal vs. hemodialysis 1.25 (1.09 to 1.45) 1.54 (1.32 to 1.78)
Bleeding likely peptic ulcer related 0.99 (0.92 to 1.07) 0.93 (0.86 to 1.01)
Hospitalized bleeding episode 2.17 (1.86 to 2.54) 2.11 (1.80 to 2.48)
Diabetes 1.11 (1.02 to 1.20) 1.06 (0.97 to 1.15)
Hypertension 1.07 (0.98 to 1.16) 0.91 (0.83 to 0.99)
Heart failure 1.56 (1.44 to 1.68) 1.21 (1.11 to 1.32)
Cerebrovascular disease 1.44 (1.31 to 1.57) 1.22 (1.11 to 1.34)
Arrhythmia 1.67 (1.55 to 1.80) 1.29 (1.19 to 1.40)
Cancer 1.85 (1.65 to 2.07) 1.58 (1.40 to 1.77)
Chronic liver disease 1.43 (1.29 to 1.58) 1.59 (1.43 to 1.76)
Chronic obstructive pulmonary disease 1.53 (1.41 to 1.65) 1.20 (1.10 to 1.30)
Peripheral vascular disease 1.60 (1.48 to 1.72) 1.32 (1.22 to 1.44)
Valvular heart disease 1.48 (1.37 to 1.60) 1.20 (1.11 to 1.31)
History of kidney transplantation 0.77 (0.65 to 0.92) 0.98 (0.82 to 1.19)
History of ANVUGIB 0.79 (0.73 to 0.86) 0.76 (0.70 to 0.82)
Coronary artery disease* 1.24 (1.15 to 1.34)
Among men 0.87 (0.78 to 0.98)
Among women 1.04 (0.92 to 1.18)
Abbreviations: ANVUGIB – acute nonvariceal upper gastrointestinal bleed; CAD – coronary artery disease.
* There was evidence for effect modification between sex and CAD in fully-adjusted models. Therefore, effect estimates are presented for sex within strata of CAD
and for CAD within strata of sex. All estimates arose from models that were adjusted for calendar year, age, gender, race, dialysis vintage, modality, history of
renal transplantation, prior ANVUGIB, hospitalized episodes, peptic ulcer related episodes, comorbidities (including diabetes, heart failure, coronary artery disease,
chronic obstructive pulmonary disease, cerebral vascular disease, hypertension, arrhythmia, valvular heart disease, peripheral vascular disease, chronic liver disease
and malignancy), and interaction between sex and coronary artery disease.
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an initial episode of ANVUGIB and be aware of the
heightened mortality risk in patients experiencing an
initial bleed.
In the dialysis population, black individuals experience
better long-term survival then whites [27,28]. Compared
to white patients in our cohort, black patients also had
significantly lower risk for 30-day mortality after ANVUIGB
(OR: 0.80; 99% CI: 0.73-0.87) after multivariable adjust-
ments. In the general population, race has been rarely
linked to poor outcome after UGIB. Among elderlypatients admitted with GIB using data from Medicare
Provider Analysis and Review (MedPAR) File and the
VA Patient Treatment File (PTF), 30-day mortality for
black patients was 6.8%, compared with 7.8% for white
patients (p<0.05). The difference remained significant
(1.4%; p<0.05) after adjustment for baseline comorbid
conditions, socioeconomic variables, and hospital effects
[29]. The racial disparities in short-term outcome after
ANVUGIB might result from biologically racial differences
of gastrointestinal pathology or stress reactions which
deserve further study.
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acknowledge certain limitations. The most important
limitation stems from the use of administrative billing
claims to identify the event of interest. However, the
algorithm we used to identify ANVUGIB episodes had
been validated by Cooper et al. [30] and modified by
Targowinik et al. [8]. In addition, we applied a rather
stringent criterion to ascertain ANVUGIB episodes to
increase the specificity of the algorithm. Nevertheless,
severe episodes from which patients died before ANVUGIB
could be diagnosed or coded may not have been captured
by our data.
Another limitation is that we did not have information
on biometric measurements, laboratory results and
endoscopic findings. Hence, the c-statistic of the fully-
adjusted model was only 0.68. However, in daily practice,
such clinical characteristics may remind clinicians of higher
risk of short-term mortality from ANVUGIB in patients on
dialysis, even before laboratory data or endoscopy findings
are available.
In order to ensure correct ascertainments of co-mor-
bidities status from claims, we further restricted our
cohort to only those patients under Medicare as primary
payer for at least one year before the ANVUGIB dates.
Thus, the median dialysis vintage of this cohort (3.8
years) was longer than that of the general prevalent
dialysis population and we do not know whether our
results generalize to those patients dialyzed for less than
one year or to those who have primary payers other than
Medicare.Conclusions
In conclusion, patients on dialysis represent a unique
subgroup of patients with ANVUGIB exhibiting high
risk for mortality and distinct risk factors. Patients with
older age, longer dialysis vintage, several co-morbidities,
no previous history of ANVUGIB, and those receiving
peritoneal dialysis were at higher risk for 30-mortality
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